In recent years, we have demonstrated the anti-angiogenic potential of POMC therapy in pre-clinical animal models of diseases due to excessive angiogenesis such as B16-F10 melanoma [15,16], Lewis lung carcinoma [16], and osteoarthritis [36]. This evidence concerns the gene POMC and osteoarthritis.